Update date
29 Jan 2026
Universe Pharmaceuticals INC financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q3 2025.
- Public ticker
- UPC on Nasdaq
- Latest financial report
- 29 Jan 2026
- Company location
- Ji'an, Jiangxi, China
- Fiscal year end
- 30 September
Company
Names, identifiers, and filing context for this profile.
1 identity field
SEC filing record 1 source field available
Shareable Research Card
UPC - Universe Pharmaceuticals INC Financial Facts
UPC - Universe Pharmaceuticals INC has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.
Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.
- Context
- Latest metrics period: Q3 2025
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Return Loop
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q3 2025
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q3 2025.
- Most recent SEC facts end date on this page: 30 Sep 2025.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for UPC - Universe Pharmaceuticals INC
Latest financial period: Q3 2025. Reopen this facts page to verify the newest reported period against the prior baseline.
Page type
Company facts
Latest period
Q3 2025
SEC-backed company facts were refreshed from filings filed on 29 Jan 2026.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Key facts
- UPC - Universe Pharmaceuticals INC financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q3 2025.
- Headline metric summary will appear when SEC facts are available.
Change
- No metrics are currently available for comparison on this facts page.
- Changes will populate automatically as new 10-Q/10-K periods are processed.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
DCF value materially below price
Overvalued
Low confidence
-2772813%
fair value gap
Fair value per share
$168026.42
Market price
$6.06
UPC - Local security
PEG ratio
n/a
Enterprise value
$76.61B
Equity value
$76.6B
DCF fair value scenarios
Bear
$125397.34
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Gap -2069363%
Base
$168026.42
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Gap -2772813%
Bull
$235147.79
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Gap -3880427%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
n/a
Local security market EV / SEC revenue
Market enterprise value is unavailable
EV/EBITDA
n/a
Local security market EV / SEC EBITDA
Market enterprise value is unavailable
P/E
n/a
Local security market price / SEC EPS
Net income is unavailable or not positive
P/S
0.0x
Local security market cap / SEC revenue
P/B
0.0x
Local security market cap / SEC equity
PEG
n/a
P/E / DCF Growth Assumption
P/e or positive growth is unavailable
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- $5.26B
- Trailing SEC FCF
- Reported FCF
- $5.26B
- Net income
- $3.67B
- EBITDA
- $2.4B
- Cash
- $14.24M
- Debt
- n/a
- Equity
- $56.13M
- Shares
- 455,871
Data confidence notes
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Dcf base free cash flow: trailing free cash flow is not positive
- Dcf confidence is low for this sec-only free cash flow estimate
- Debt missing: equity value treats debt as 0
- Base free cash flow is negative; dcf output is mechanically computed but high risk
- Peg unavailable: earnings per share is not positive
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
n/a
Insufficient Data Confidence low
Financial Health
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 563,338 | -98% |
| Common Stock, Shares, Outstanding | 563,338 | +1214% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY change |
|---|---|---|
| Accounts Payable, Current | $1,669,785,000 | +33875% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $13,008,117 | +0.79% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $1,813,522 | |
| Assets | $69,303,440 | +2% |
| Assets, Current | $53,603,675 | +3.8% |
| Common Stock, Shares Authorized | 2,000,000,000 | 0% |
| Common Stock, Shares, Issued | 563,338 | +1214% |
| Contract with Customer, Liability, Current | $40,708,000 | |
| Deferred Tax Assets, Valuation Allowance | $2,167,162,000 | -1.4% |
| Liabilities | $13,173,930,000 | -41% |
| Liabilities and Equity | $69,303,440 | +2% |
| Liabilities, Current | $13,173,930 | |
| Preferred Stock, Par or Stated Value Per Share | 11.25 | |
| Preferred Stock, Shares Authorized | 1,250,000 | |
| Property, Plant and Equipment, Gross | $10,487,306 | +2.5% |
| Property, Plant and Equipment, Net | $3,583,553 | +0.43% |
| Retained Earnings (Accumulated Deficit) | $13,843,623 | |
| Stockholders' Equity Attributable to Parent | $56,129,510 | +23% |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
CIK / security context first